New India Assurance vs Star Health (2026): PSU General Insurance, Claims & Which Is Better?
New India Assurance vs Star Health (2026): PSU General Insurance, Claims & Which Is Better?
New India Assurance and Star Health represent almost opposite general-insurance models. New India Assurance is a century-old diversified PSU insurer writing health, motor, fire, marine and international business. Star Health is a specialist built overwhelmingly around medical insurance. Q1 FY27 made that contrast unusually visible: New India Assurance produced more than three times Star's gross premium but suffered a 121.44% combined ratio and a quarterly loss, while Star delivered 19% premium growth and positive underwriting profit.
The easiest mistake in this comparison is assuming that the company with the larger premium book must have the stronger insurance economics.
It does not.
Premium is useful only when it is priced well enough to cover claims, commissions and operating expenses.
A general insurer can grow revenue while destroying underwriting value.
That is why the central equation is:
Premium − claims − commissions − expenses = underwriting result.
Investment income then sits on top of that underwriting engine.
For Bull Run's market data, see New India Assurance, Star Health and the General Insurance sector dashboard. A related specialist-versus-diversified comparison is ICICI Lombard vs Star Health.
Q1 FY27 operating comparison
| Metric | New India Assurance | Star Health | Interpretation |
|---|---|---|---|
| Gross premium | GWP ₹13,720 cr, +2.9% | Reported 1/N GWP ₹4,287 cr, +19% | New India is over three times larger; Star grew much faster. |
| Primary claims metric | Incurred claim ratio 103.38% | Ind-AS analytical loss ratio about 67.5% | New India's claims alone exceeded the relevant premium denominator; accounting frameworks differ. |
| Underwriting ratio | Combined ratio 121.44% | Company-defined CISR 97.0% | Star reported profitable insurance-service economics; exact percentages are not definitionally identical. |
| Underwriting result | Approx. ₹2,356 cr underwriting loss in standalone Q1 disclosures | ₹111 cr underwriting profit | The operating contrast is much clearer than a mechanical ratio comparison. |
| PAT | Loss ₹257 cr | Ind-AS PAT ₹550 cr | Star earned more despite writing much less premium. |
| Normalised profitability | No comparable company normalisation used here | ₹386 cr normalised PAT at 8% assumed annual investment yield | Star separately strips out unusually strong/weak investment-market effects. |
| Solvency | 1.80x | 2.09x | Both exceed 1.50x regulatory minimum; Star has the larger current percentage buffer. |
| Investment assets / assets | Investment assets about ₹99,980 cr on market-value basis | Investment assets about ₹21,893 cr | New India's investment float is far larger. |
New India Assurance's problem begins before investment income
New India Assurance's Q1 combined ratio was 121.44%.
A combined ratio above 100% means the insurer is losing money on underwriting before considering investment income.
At 121.44%, the gap is not marginal.
For every ₹100 of relevant earned premium, claims and operating costs consumed roughly ₹121.44 on the company's reported basis.
The insurer's incurred claim ratio alone was 103.38%.
That means claims exceeded premium before commissions and management expenses were even added.
This is fundamentally different from a company operating at 101–103%, where small pricing, claims or expense changes can restore underwriting profitability.
Where did the underwriting pressure come from?
New India Assurance's Q1 portfolio shows that the weakness was not caused by one tiny line of business.
Health and personal accident remained its largest segment, with GWP of roughly ₹6,819 crore, close to half the overall premium book.
Its health and personal-accident incurred-claims ratio remained above 100%.
Motor was also problematic.
Motor Third Party incurred claims were especially weak, with the ratio above 120% in Q1.
Management and the company's public financial commentary explicitly highlighted the absence of adequate Motor TP tariff revision as a driver of the elevated overall claim ratio.
New India's health book is larger than Star Health's entire quarterly GWP
This is one of the most important scale observations.
New India Assurance wrote roughly ₹6,819 crore of health and personal-accident GWP in Q1.
Star Health's total reported 1/N GWP across its specialist franchise was ₹4,287 crore.
New India's health-related premium pool is therefore enormous.
The problem is not access to customers.
The problem is monetising that access profitably.
That makes New India fundamentally different from an early-stage insurer attempting to build scale.
It already has scale.
It needs underwriting repair.
Star Health has the opposite problem
Star does not need to repair a sprawling fire, motor, marine and international portfolio.
Its strategic concentration is health insurance.
That allowed Q1 GWP to increase 19% year on year.
Fresh retail-health GWP increased 37% to ₹730 crore on the reported 1/N basis.
Approximately 94% of fresh retail business was reported as new-to-insurance customers.
That suggests Star is expanding the category rather than merely stealing renewals from competitors.
Growth only matters because Star's underwriting improved at the same time
High health-insurance growth is dangerous if it comes from inadequate pricing.
Medical inflation often appears after the original sale.
An insurer can report excellent premium growth today and discover a year later that hospital bills were priced incorrectly.
Star's Q1 was encouraging because premium growth and underwriting improvement occurred simultaneously.
Underwriting profit increased from only ₹16 crore to ₹111 crore.
The company-defined Combined Insurance Service Ratio improved from 98.7% to 97.0%.
Its analytical loss ratio improved to around 67.5%.
That is a healthier pattern than volume growth accompanied by worsening claims.
Why Star's 97% CISR and New India's 121.44% combined ratio are not perfectly comparable
Star Health transitioned to Ind AS in FY27.
Its 97.0% CISR is a company-defined insurance-service ratio under that new framework.
New India Assurance's 121.44% combined operating ratio comes from its existing regulatory general-insurance reporting structure.
Although both answer a similar economic question — whether claims and insurance costs exceed premium/revenue — the detailed accounting components differ.
Investment float explains why general insurers can survive underwriting losses
Insurance premium is collected before many claims are finally paid.
The insurer invests that money in the meantime.
This produces float.
New India Assurance has an enormous investment portfolio.
The company's June commentary put investment assets at approximately ₹99,980 crore on market-value basis.
That generates substantial investment income.
Q1 standalone disclosures showed investment income of more than ₹2,000 crore.
Without that investment engine, the underwriting loss would translate much more directly into shareholder losses.
Yet the investment portfolio could not fully offset Q1 underwriting weakness, and PAT still moved to a ₹257 crore loss.
Why investors should not celebrate investment income that repeatedly repairs underwriting
A diversified insurer can rationally operate around a combined ratio near 100% if the investment portfolio earns a strong return.
That is a legitimate insurance model.
But a combined ratio above 120% requires much more investment income simply to break even.
That creates three risks:
- investment returns may fall,
- bond or equity markets can be volatile,
- weak underwriting can consume capital even when investment income looks large.
The long-term objective should therefore be improving claims and expense economics rather than assuming the investment book will indefinitely subsidise underwriting.
Star also earns important investment income — but Q1 did not depend on it for underwriting profit
Star Health generated investment income of around ₹644 crore in Q1 under its Ind-AS presentation.
Its reported PAT was ₹550 crore.
Because market-linked investment returns can move materially, management also presents a normalised PAT based on an assumed 8% annual investment yield.
That normalised PAT was ₹386 crore, up 44% year on year.
This distinction is useful.
The ₹550 crore reported PAT includes actual investment-market effects.
The ₹386 crore normalised figure gives investors a steadier view of earnings under a standardised investment-return assumption.
Neither should replace the other.
The specialist-versus-diversified trade-off
New India Assurance
- Health and personal accident.
- Motor own damage.
- Motor third party.
- Fire and commercial risk.
- Marine and engineering.
- International operations.
- Very large investment float.
Advantage: one claims cycle does not define the entire company.
Problem: several weak lines can make portfolio repair slow.
Star Health
- Retail health.
- Group health.
- Personal accident.
- Small adjacent health-related categories.
- Medical claims infrastructure.
- Large proprietary agency network.
- Health-specific claims data.
Advantage: deep specialisation and focused data.
Problem: medical inflation affects almost the whole franchise.
Star's specialist moat is mostly claims data and distribution
Health insurance becomes more defensible as an insurer accumulates longitudinal claims data.
Hospital pricing varies.
Procedure utilisation differs by geography.
Provider fraud patterns develop over time.
Customer age, pre-existing disease, sum insured and treatment behaviour all interact.
A specialist with years of claims history can potentially price these risks more precisely than an insurer treating health as one of many business lines.
Star also operates a very large agency-driven distribution network and increasingly uses digital tools throughout policy issuance and claims servicing.
Management highlights more than two decades of proprietary health-insurance data as a strategic asset.
But medical inflation can overwhelm even strong historical data
Hospitals can increase room rates.
New medical technologies can raise average procedure costs.
Customers may seek higher-cost treatments.
Claim frequency can change after pandemics or disease outbreaks.
Regulation can affect exclusions, waiting periods and product terms.
Because Star is concentrated in health, a 300-basis-point deterioration in medical loss ratio can affect a large share of group earnings simultaneously.
New India has more diversification against that particular risk.
New India's PSU structure creates a different operating constraint
New India Assurance is a public-sector general insurer.
That gives it advantages in brand recognition, corporate relationships, government-linked business and nationwide reach.
It can also create a different optimisation problem.
Private insurers can more aggressively refuse poorly priced segments when they believe shareholder returns are inadequate.
A PSU insurer may operate with broader historical responsibilities, legacy portfolios and institutional relationships.
This does not automatically explain every weak combined ratio.
But it helps explain why restructuring a century-old portfolio can take longer than adjusting one specialist product line.
Motor Third Party is New India's most difficult structural issue
Motor TP premium is regulated differently from freely priced motor own damage.
Claims can be long-tail and court-driven.
A policy sold today can generate a liability that remains unresolved for years.
If bodily injury awards rise but tariffs fail to adjust adequately, insurers accumulate reserve pressure.
New India explicitly identified the lack of premium revision in Motor TP as an important reason its Q1 incurred-claim ratio deteriorated.
This is not a problem management can solve only through better app design or distribution productivity.
Pricing regulation matters.
Health claims are high too
New India's health and PA incurred-claim ratio remained above 100%.
That implies claims alone consumed more premium than the line produced on the relevant regulatory basis.
Star's analytical health loss ratio was around 67.5% under its Ind-AS presentation.
Again, the definitions are not perfectly equivalent.
But the scale of the difference indicates that Star is currently selecting and pricing medical risk more profitably.
Solvency: Star currently has more headroom
New India Assurance reported a solvency ratio of 1.80x.
Star Health reported 2.09x.
Both remain above the 1.50x minimum.
New India's ratio is adequate, but it has less room to absorb sustained underwriting losses before capital optimisation becomes more important.
Star's higher solvency provides more current room to fund growth and absorb claim volatility.
Valuation: New India looks cheap on reported net worth, but there is a reason
New India Assurance's August 25 Bull Run market capitalisation was approximately ₹29,629 crore.
The company reported June net worth including fair-value changes of approximately ₹39,447 crore.
That equates to roughly 0.75x market capitalisation to that reported net-worth measure.
Star Health's August market capitalisation was approximately ₹35,029 crore.
Its June Ind-AS total equity was approximately ₹10,144 crore.
That gives an indicative market-cap-to-equity multiple of approximately 3.45x.
Market cap / reported net worth including fair-value changes.
Market cap / June Ind-AS total equity.
This is not a clean apples-to-apples P/B comparison.
The companies are using different accounting presentations, and New India's net-worth figure explicitly includes fair-value changes.
The calculation is useful only to show how differently the market values the two franchises.
Star is being valued for future profitable growth.
New India is being valued with a large discount for weak underwriting returns.
Cheap equity is not automatically undervalued equity
An insurer trading below reported net worth can remain below net worth for years if underwriting destroys capital.
For New India to deserve a materially higher valuation, it needs evidence that:
- combined ratio is moving sustainably toward 100%,
- Motor TP claims economics are improving,
- health pricing produces better loss ratios,
- expense growth is controlled,
- investment income becomes additive rather than compensatory.
Without those changes, the discount can be economically justified.
Star's valuation requires the opposite proof
Star already trades at a substantial premium to equity.
The market therefore expects:
- mid-to-high-teens premium growth,
- sub-100 company-defined CISR,
- stable or improving medical loss ratios,
- continued agency productivity gains,
- healthy renewal behaviour,
- mid-teens normalised ROE.
If claims deteriorate, a premium valuation leaves much less room for disappointment.
Stock-market snapshot
| August 25, 2026 Bull Run snapshot | New India Assurance | Star Health |
|---|---|---|
| Price | ₹187.29 | ₹582.85 |
| Market capitalisation | ₹29,628.77 cr | ₹35,029.24 cr |
| 1-month return | +8.14% | -0.99% |
| 3-month return | +16.65% | +11.09% |
| 6-month return | +25.72% | +22.95% |
| 1-year return | -2.36% | +31.42% |
| 52-week high / low | ₹218.00 / ₹116.97 | ₹623.90 / ₹416.55 |
| RSI (14) | 74.00 | 49.17 |
| Dividend yield | 0.83% | 0% |
| Bull Run Score | 39.4 | 61.1 |
New India's strong six-month rebound pushed its RSI above 70 in the Bull Run snapshot.
Star had the stronger one-year stock performance but more neutral short-term momentum.
These technical measures are secondary to underwriting quality.
What does New India need to fix first?
What does Star need to prove?
Star's challenge is not turnaround from a 121% combined ratio.
Its challenge is proving that the current improvement survives difficult seasonal periods.
Q2 often carries higher health claims because of monsoon-related illnesses and vector-borne disease.
If Star can preserve disciplined loss ratios through those periods while growing premium in the mid-to-high teens, confidence in the underwriting turnaround should rise.
New India Assurance vs Star Health: which wins each category?
| Question | Current edge | Reason |
|---|---|---|
| Larger premium franchise? | New India Assurance | ₹13,720 crore Q1 GWP versus Star's ₹4,287 crore reported 1/N GWP. |
| Faster premium growth? | Star Health | 19% versus New India at 2.9%. |
| Better current underwriting direction? | Star Health | ₹111 crore underwriting profit versus a very large underwriting loss at New India. |
| Lower reported claims burden? | Star Health directionally | Star's analytical loss ratio was around 67.5%; New India's regulatory incurred-claim ratio was above 103%, with framework caveat. |
| Greater diversification? | New India Assurance | Health, motor, fire, marine, engineering and international business. |
| Stronger health specialisation? | Star Health | Health insurance is the core franchise, data set and claims infrastructure. |
| Higher solvency? | Star Health | 2.09x versus New India at 1.80x. |
| Larger investment float? | New India Assurance | Approximately ₹99,980 crore of investment assets on market-value basis. |
| Lower indicative equity valuation? | New India Assurance | Market value is below its reported net worth including fair-value changes, subject to accounting caveat. |
| Stronger current operating franchise? | Star Health | Faster growth combined with positive underwriting economics. |
Which is stronger in 2026?
Star Health currently has the stronger insurance operating economics.
It is growing much faster, underwriting profit is improving, claims economics are moving in the right direction and solvency is comfortable.
New India Assurance has far greater diversification, investment scale and valuation optionality.
But that optionality cannot become durable shareholder value without underwriting repair.
The company does not need to become a specialist health insurer.
It needs a diversified portfolio in which each major segment is priced closer to sustainable economic cost.
The current valuation discount is therefore best viewed as a turnaround discount rather than free upside.
What to monitor next
- New India combined ratio: the central turnaround metric.
- New India Motor TP claim ratio: currently a major source of structural pressure.
- New India health claim ratio: scale has limited value if claims remain above premium.
- New India expense ratio: cost growth should not continue to exceed premium growth.
- Star CISR: remaining below 100% through seasonal health claims would strengthen the thesis.
- Star retail loss ratio: the most direct health-underwriting signal.
- Star fresh retail growth: 37% growth must translate into persistent renewal premium.
- Star normalised ROE: better long-run measure than investment-market-driven quarterly PAT.
Frequently asked questions
Which is larger, New India Assurance or Star Health?
New India Assurance is much larger by premium. It reported Q1 FY27 GWP of ₹13,720 crore versus Star Health's reported 1/N GWP of ₹4,287 crore.
Which had better underwriting performance?
Star Health. It reported ₹111 crore of Q1 FY27 underwriting profit and a 97.0% company-defined CISR, while New India Assurance reported a 121.44% combined ratio and a large underwriting loss.
Why did New India Assurance report a loss?
Its incurred-claim ratio rose above 103% and combined ratio reached 121.44%, driven by high claims — particularly Motor TP — and higher operating expenses. Investment income was not enough to fully offset the underwriting loss.
Which has higher solvency?
Star Health reported a solvency ratio of approximately 2.09x at June 2026 versus New India Assurance at 1.80x. Both remain above the 1.50x regulatory minimum.
Is Star Health less risky because its claims ratio is lower?
Not automatically. Star has better current underwriting metrics but is concentrated in health insurance, making it more exposed to medical inflation and hospital-cost cycles. New India is much more diversified.
Why does New India Assurance trade below reported net worth?
The market applies a discount because the insurer currently produces weak underwriting returns. A low market-to-net-worth multiple becomes more meaningful only if claims, expenses and combined ratio improve sustainably.
Which company is the stronger franchise today?
Star Health currently has the stronger operating and underwriting trajectory. New India Assurance has more scale and diversification but needs a material underwriting turnaround.